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ABSTRACT

Intracellular delivery of cell-impermeable compounds in a variety cells using
delivery systems have been extensively studied in recent years. Obtaining desirable
cellular uptake levels often requires the administration of high quantities of drugs to
achieve the expected intracellular biological effect. Thus, improving the translocation
process across the plasma membrane will significantly reduce the quantity of required
administered drug and consequently minimize the side effects in most of the cases.
Efficient delivery of these molecules to the cells and tissues is a difficult challenge.
Compounds with low cellular permeability are commonly considered to be of limited
therapeutic value. Over the past few decades, several biomedical carriers, such as
polymers, nanospheres, nanocapsules, liposomes, micelles, peptides and dendrimers have
been widely used to deliver therapeutic and diagnostic agents to the cells. Biomaterials
generated from nano-scale compounds have shown some promising data for delivery of
many compounds in a number of diseases, such as viral infections, cancer, and genetic
disorders. Although much progress has been achieved in this field, many challenges still
remain, such as toxicity and limited stability.
Liposomes suffer from poor stability in the bloodstream and leakage during
storage. They tend to aggregate and fuse with or leak entrapped drugs, especially highly
hydrophilic small molecules. For solid lipid nanoparticles (SLNs), drug expulsion after
polymorphic transition during storage, inadequate loading capacity, and relatively high
water content of the dispersions have been observed.

Poly lactic-co-glycolic acid (PLGA) degrades in the body producing its original
monomers of lactic acid and glycolic acid, which are the by-products of various
metabolic pathways. However, this acidic microenvironment that occurs during
degradation could negatively affect the stability of the loaded compound. Dendrimers
can carry drugs as complexes or as conjugates although one limitation lies in the effort of
controlling the rate of drug release. The encapsulated or complexed drugs tend to be
released rapidly (before reaching the target site) and in the dendrimer–drug conjugates, it
is the chemical linkage that controls the drug release. Thus, future studies in this field are
urgently required to create more efficient and stable biomaterials.
Peptides are considered as efficient vectors for achieving optimal cellular uptake.
The potential use of peptides as drug delivery vectors received much attention by the
discovery of several cell-penetrating peptides (CPPs). The first CPPs, discovered in 1988,
were sequences from HIV-1 encoded TAT protein, TAT (48–60), and penetrated very
efficiently through cell membranes of cultured mammalian cells. CPPs are a class of
diverse peptides, typically with 8–52 amino acids, and unlike most peptides, they can
cross the cellular membrane with more efficiency. CPPs have also shown to undergo selfassembly and generate nanostructures. The generation of self-assembled peptides and
nanostructures occur through various types of interactions between functional groups of
amino acid residues, such as electrostatic, hydrophobic, and hydrogen bonding.
Appropriate design and functionalization of peptides are critical for generating
nanostructures.

Chemically CPPs are classified into two major groups: linear and cyclic peptides.
It has been previously reported that linear peptides containing hydrophilic and
hydrophobic amino acids could act as membrane protein stabilizers. These compounds
are short hydrophilic or amphiphilic peptides that have positively charged amino acids,
such as arginine, lysine or histidine, which can interact with the negative charge
phospholipids layer on the cell membrane and translocate the cargo into the cells.
Conjugation to cationic linear CPPs, such as TAT, penetratin, or oligoarginine
efficiently improves the cellular uptake of large hydrophilic molecules, but the cellular
uptake is predominantly via an unproductive endosomal pathway. Therefore, the
biological effect is very limited, as the compounds are trapped in these compartments and
cannot reach their biological targets in the cytoplasm or the nucleus. Mechanisms that
promote endosomal escape or avoid endosomal route are required for improving
bioavailability. Highly cationic CPPs preferentially interact with particular cell types,
have limited plasma half-life, show toxicity, do not cross multicellular barriers such as
vasculature epithelia or the blood-brain barrier, and efficient cargo delivery requires 9-15
arginine residues. Highly cationic CPPs are, therefore not ideal small molecule drug
delivery vehicles. Linear CPPs are susceptible to hydrolysis by endogenous peptidases.
Conjugation to cationic CPPs, such as TAT, penetratin, or oligoarginine efficiently
improves the cellular uptake of large hydrophilic molecules, but the cellular uptake
occurs predominantly via an unproductive endosomal pathway. Therefore, the biological
effect is very limited, as the compounds are trapped in these compartments and cannot
reach their biological targets in the cytoplasm or the nucleus.

Mechanisms that promote endosomal escape or avoid endosomal route are
required for improving bioavailability. Highly cationic CPPs preferentially interact with
particular cell types, have limited plasma half-life, show toxicity, do not cross
multicellular barriers such as vasculature epithelia or the blood-brain barrier, and efficient
cargo delivery requires 9-15 arginine residues. Highly cationic linear CPPs are, therefore,
have not become optimized as small molecule drug delivery vehicles.
On the other hand, cyclic peptides containing hydrophilic and hydrophobic amino
acids have shown greater potential as drug delivery tools due to their enhanced chemical
and enzymatic stability. Parang's laboratory has reported that Amphiphilic Cyclic
Peptides (ACPs) containing positively charged arginine and hydrophobic tryptophan
residues as potential candidates for drug delivery. Cyclic peptides have several benefits
compared to linear peptides, such as rigidness of structure and stability against
proteolytic enzymes. The rigidity of the structure can enhance the binding affinity of
ligands toward receptors by reducing the freedom of possible structural conformations.
Cyclic peptides are also present in nature and have been developed as therapeutics.
Cyclosporine, gramicidin S, polymoxin B, and daptomycin are well-known examples of
cyclic peptide drugs. Parang's laboratory designed amphiphilic cyclic CPPs containing
alternative tryptophan and arginine residues as the positively charged and hydrophobic
residues, respectively. The peptides were efficient in improving the cellular delivery of
anticancer and antiviral drugs.

The cellular uptake mechanism of CPPs into cells is still a matter of some debate.
The cellular entry of CPP can be influenced by the type of CPP, the cell line, the nature
of the cargo, and the conditions of incubation. As described above, linear CPPs pass
through the plasma membrane mostly via an energy-independent or endocytosis pathway.
Moreover, the cellular delivery of CPP-conjugated molecules also occurs through
endosomal pathway and a strong enzymatic degradation and an inadequate cytoplasmic
release of intact molecules from the conjugates are expected, thus leading to an
inefficient transfer into the cytoplasm. The best strategy to overcome this issue is to
designing CPP that by pass the endosomal uptake or by increasing the escape rate from
the endosome to improve the intracellular delivery of CPP-attached molecules.
Parang laboratory has reported the cellular uptake of a number of cyclic peptides
independent of endocytotic pathway. The extraordinary ability of cyclic peptides
containing tryptophan and arginine, [WR]4 and [WR]5 to spontaneously translocate
across bilayers independent of an energy source is distinctly different from the behavior
of the well-known, highly cationic CPPs, such as TAT and Arg9, which do not translocate
across phospholipid bilayers, and enter cells mostly by active endocytosis.
Alternatively, researchers have found that an effective cellular delivery vector can
be improved developed by conjugating a CPP with a fatty acid chain. Amphiphilic
peptides have also become a subject of major interest as potent antibacterial agents.
Antimicrobial peptides (AMPs) are produced naturally by bacteria and are considered as
the first line of host defense protecting against microbial infection. Various types of
AMPs have been discovered, such as defensins, cecropins, magainins and cathelicidins,
with significant different structures and bioactivity profiles.

These peptides are reported to be effectors and regulators of the innate immune
system by increasing production and release of chemokines, and enhance wound healing
and angiogenesis. They are able to suppress biofilm formation and induce the dissolution
of existing biofilms. Thus, design of new AMPs with higher activity are urgently needed.
Although a number of cyclic peptides were discovered and reported as efficient
cellular delivery agents and/or antimicrobial agents, a more systematic investigation is
required to identify design rules for optimal entrapment, drug loading, and stability.
The balance of many small forces determines the overall morphology, size, and
functionality of the structures. A deeper understanding of these factors is required for
guiding future research, and for customizing cyclic peptides for drug loading and cellular
delivery applications.
Thus, additional amphiphilic cyclic and linear peptides with variable electrostatic
and hydrophobic residues were designed here to optimize drug encapsulation. The
diversity in ring size, amino acid number, position and sequences, number of rings, net
charge, and hydrophobicity of side chains in cyclic peptides will allow us to explore
requirements for generating peptides with optimized drug encapsulation and to establish
correlations between the structure of peptides with their drug entrapment properties.
Thus, the general objective of this dissertation was to design and evaluate additional
cyclic or amphiphilic peptides as nanostructures and to compare their efficiency in
delivery of small molecules with the previously reported cyclic peptides containing
tryptophan and arginine residues. This dissertation consists of three chapters.

Chapter 1. MANUSCRIPT І (published in Current Organic Chemistry 2014).
The objective of this work was to design amphiphilic linear and cyclic peptides
containing hydrophobic tryptophan W residues that were linked through a triazole ring to
positively charged arginine (R) and lysine (K) residues. The peptides were synthesized
through click chemistry between hydrophobic peptides containing alkyne and positively
charged peptides containing azide groups. Their structures were investigated using
solubility tests, circular dichorism (CD), and transmission electron microscopy (TEM),
cytotoxicity assays. The conjugates showed minimal cytotoxicity in two cell lines. The
secondary structures of both peptides were similar to a distorted α-helix as shown by CD
spectroscopy. TEM imaging also showed that linear-linear (WG(triazole-KR-NH2))3 and
cyclic-linear [WG(triazole-KR-NH2)]3 peptides formed nano-sized structures.
Chapter 2. MANUSCRIPT ІI (Submitted to Journal of Molecular Modeling). In
this work, we investigated the structural and dynamical aspects of cyclic-linear peptide
([WG(triazole-KR-NH2)]3 and linear-linear peptide (WG(triazole-KR-NH2))3) formed
nanostructures compared to a drug delivery system with [WR]4. While [WR]4 was found
to be an efficient molecular transporter for small molecule drugs, such as lamivudine and
dasatinib, cyclic-linear peptide ([WG(triazole-KR-NH2)]3 was inefficient. Molecular
modeling was used to explain the differential behavior of these peptides. We showed how
the morphology of these systems can affect the drug delivery efficiency. The result of this
work provided insights about optimizing the amphiphilic cyclic-linear trizaolyl peptides
with more efficient drug delivery capabilities.
Chapter 3. MANUSCRIPT ІII. The objective of this Chapter was to synthesize a
different series of amphiphilic peptides for different objectives. First, the amphiphilic

trizaolyl peptides in Chapter I were systematically modified by increasing the number of
arginine and tryptophan sequence in cyclic and linear peptides. The rationale for the
modification was to enhance the possibility of interaction with the cell membrane and
therefore improving the cellular uptake process. Moreover, a new class of amphiphilic
peptides consisting of tryptophan and glutamic acid were conjugated with a peptide
containing arginine and lysine residues using Fmoc-based peptide chemistry. These
peptides have an amide bond that generates more flexibility compared to a triazole ring.
Finally, additional fatty acids with different length chains were conjugated with
positively charged peptides and evaluated as antibacterial agents. Stearic acid (C16) and
myristic acid (C14) were conjugated with peptides consisting of arginine azide and lysine
amino acids to enhance the antibacterial activity.

In summary, the work in this dissertation provided insights about the synthesis
and characterization of a new class of amphiphilic triazolyl peptides as drug delivery
carriers and amphiphilic peptides as antibacterial agents. Molecular modeling was used to
explain why triazolyl peptides were unable to enhance the delivery of small molecule
drugs compared to the previously synthesized cyclic peptides [WR]4 (Chapter 2)
Modification of synthesized peptides in Chapter 1, by addition of more positively
charged amino acids or reducing the rigidity by incorporating amide bonds instead of
triazolyl groups can be used to improve the cell penetrating properties. Finally, we
conjugated amphiphilic peptides with different fatty acids (Chapter 3) to investigate their
application as antibacterial agents.
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PREFACE
This dissertation is written based on the University of Rhode Island “Guidelines
for the Format of Thesis and Dissertations” standards for Manuscript format. This
dissertation is composed of three Chapters to satisfy the requirements of the department
of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode
Island.

CHAPTER 1: MANUSCRIPT І: Amphiphilic Triazolyl Peptides: Synthesis
and Evaluation as Nanostructure.
This manuscript was published in “Current Organic Chemistry”, 2014, 18, 2665
2671”

CHAPTER 2: MANUSCRIPT II: Cyclic Peptide Nanostructures as Drug
Delivery Systems: Structural Insights and Dynamical Behavior.
This manuscript was submitted to “Journal of Molecular Modeling”.

CHAPTER 3: MANUSCRIPT III. Synthesis of Derivatives Amphiphilic Peptides.
This manuscript is in process.
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Abstract
A new class of amphiphilic triazolyl peptides were designed and synthesized from
peptide-based building blocks containing alkyne and azide functional groups namely
linear (W(pG))3, cyclic[W(pG)]3, and Ac-K(N3)R-NH2, where W, R, K, and pG represent
tryptophan, arginine, lysine, and propargylglycine residues, respectively. The linear
(W(pG))3 and cyclic [W(pG)]3 peptides containing alkyne residues were conjugated with
Ac-K(N3)R-NH2 functionalized with azide group through click chemistry in the presence
of CuSO4.5H2O, Cu (powder), sodium ascorbate, and N,N-disopropylethylamine in
methanol:water to afford amphiphilic triazolyl linear-linear (WG(triazole-KR-NH2))3 and
cyclic-linear [WG(triazole-KR-NH2)]3 peptides, respectively. The secondary structures of
both peptides were similar to a distorted α-helix as shown by CD spectroscopy. TEM
imaging

showed

that

linear-linear

(WG(triazole-KR-NH2))3

and

cyclic-linear

[WG(triazole-KR-NH2)]3 peptides formed nano-sized structures in the size range of 50100 nm and 50-80 nm, respectively.

Keywords: Amphiphiles, Click chemistry, Cyclic peptides, Nanoparticles, Peptides,
Triazole.
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1. Introduction

Design and synthesis of well-defined materials in nano-sized structures have
turned into an important field in biomaterials science and biomedicine.1,2 Different intra
and intermolecular forces, such as electrostatic interaction, hydrogen bonding,
hydrophobic forces, and aromatic stacking contribute to the formation of organized
structures.3-5
Peptides have become a subject of major interest because of their unparalleled
potential applications as nanomaterials, surfactants, and drug delivery systems.6-8 Linear
and cyclic peptides containing appropriate amino acids have been shown to undergo selfassembly and generate nanostructures.9 The generation of self-assembled peptides and
nanostructures occur through various types of interactions between functional groups of
amino acid residues, such as electrostatic, hydrophobic, and hydrogen bonding.
Appropriate design and functionalization of peptides are critical for generating
nanostructures.
Peptides are divided into two major groups namely linear and cyclic. Linear
peptides adopt higher flexibility in a solution compared to their cyclic counterparts.
Moreover, peptide cyclization has been used as an effective strategy to decrease the
conformational freedom of the peptides and to improve the stability against different
proteolytic enzymes, such as trypsin, α-chymotrypsin, and dipeptidyl-peptidase IV.10 It
has been previously shown that linear peptides containing hydrophilic and hydrophobic
amino acids could act as membrane protein stabilizers.11
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However, cyclic peptides containing hydrophilic and hydrophobic amino acids
have shown greater potential as stabilizing agents due to their enhanced chemical and
enzymatic stability.12 The self-assembly of peptides has drawn significant attention
because of their simple structures and their ability to incorporate multiple inter- and
intramolecular forces.13 Depending on the desired application, various properties
including polarity, hydrophobicity, and charge in the structure of peptides can be
manipulated by using different numbers of amino acids to find an optimized balance
among different forces for self-assembly. Furthermore, the biocompatibility and low
toxicity of peptides have made them attractive tools in biomedical investigations.14 Thus,
self-assembled peptide nanostructures have employed as biomaterials,15 drug delivery
systems,16 protein stabilizers,17 and antimicrobial agents.18
We have previously reported design and synthesis of linear and cyclic peptides
containing different L-amino acids with hydrophobic (e.g., W, F, L) and charged residues
(e.g., K, R, E) by using 9-fluorenylmethyloxycarbonyl (Fmoc)-based peptide chemistry.
Among all the designed peptides, [WR]4 containing alternative tryptophan and arginine
residues generated self-assembled nanostructures at room temperature after a specific
incubation time through hydrophobic force, hydrogen bonding, and/or the π-π stacking
interactions between tryptophan residues.6 A combination of arginine and tryptophan in
the structure of cyclic peptides was also found to be an optimal sequence for drug
delivery applications.7,8 Moreover, the cyclic nature of peptides was critical in their
biological activities. For example, cyclic peptides with arginine and tryptophan residues
exhibited higher potency in kinase inhibition compared to their linear counterparts.19

4

Additional studies are required to investigate sequence effects on morphologies,
and elucidate the fundamental physical interactions that drive their self-assembly in this
class of peptides. In continuation of our efforts to explore amphiphilic peptides containing
tryptophan and arginine residues as nanostructures, herein we report a novel class of
amphiphilic triazolyl peptides containing tryptophan-based cyclic and linear peptides
linked through a triazole to positively charged linear peptides. Click chemistry was used
to attach the cyclic and linear building block peptides containing alkyne with linear
peptides functionalized with azide residues to generate cyclic-linear or linear-linear
clicked products.

2. Experimental Section
General
Reactions were carried out in Bio-Rad polypropylene columns by shaking and
mixing in Glass-Col small tube rotator under dry conditions at room temperature.
Peptides

were

synthesized

by

solid-phase

synthesis

using

N-(9-fluorenyl)

methoxycarbonyl (Fmoc)-based chemistry and employing Fmoc-L-amino acid building
blocks. H-Trp(Boc)-2-chlorotrityl resin and/or Rink amide resin were used for the
synthesis of cyclic and linear peptides, respectively. For the coupling of amino acids,
Fmoc-Trp(Boc)-OH and Fmoc-L-propargylglycine were used alternatively, 2-(1HBenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and N,Ndiisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as
coupling and activating reagents, respectively.

5

Rink amide resin, H-Trp(Boc)-2-chlorotrityl resin, coupling reagents, and Fmocamino acid building blocks were purchased from Chempep (Miami, FL). Other chemicals
and reagents were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). Fmoc
deprotection at each step was carried out using piperidine in DMF (20% v/v). The crude
peptides were purified by using a reversed-phase Hitachi HPLC (L-2455) on a Gemini
C18 column (250 mm × 21.20 cm, 10 µm) and a gradient system. The peptides were
separated by eluting the crude peptides at 10.0 mL/min using a gradient of 0-100%
acetonitrile (0.1% trifluoroacetic acid (TFA)) and water (0.1% TFA) over 60 min, and
then were lyophilized.
The purity of final products (95%) was confirmed by analytical HPLC. The
chemical structures of the building block peptides and final products were confirmed by
high-resolution MALDI AXIMA performance TOF/TOF mass spectrometer (Shimadzu
Biotech) or a high-resolution Biosystems QStar Elite time-of-flight electrospray mass
spectrometer.

Synthesis of Linear Peptide (W(pG))3
The linear peptide was assembled on Rink amide resin (0.59 g, 0.4 mmol, 0.68
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected
amino acids [Fmoc-Trp(Boc)-OH and Fmoc-L-Propargylglycine] (Scheme 1). The linear
peptide sequence was assembled on the resin after removing the Fmoc group at the Nterminal in the presence of 20% piperidine in DMF (v/v) to obtain the sequence NH2(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-Rink amide resin.
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The resin was washed with DMF (3 times, 15 mL) and DCM (3 × 15 mL) to
remove any traces of piperdine. The peptidyl resin was dried in vacuum for 24 h. A
freshly

prepared

reagent

R

cleavage

cocktail

trifluoroacetic

acid

(TFA)/thioanisole/ethandithol (EDT)/anisole (90:5:3:2, v/v/v/v, 15 mL) was added to the
resin, and the resin was agitated at room tempertuare for 2 h. The resin was collected by
filtration and consequently washed with 2 mL of reagent R. The crude peptide was
precipitated by adding peptide filterates to cold diethyl ether (200 mL, Et2O) and
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate.
The solid material was further washed with cold ether (2 × 100 mL). The peptide was
lyophilized and purified by reversed-phase Hitachi HPLC using a gradient system as
described above to yield solid white coloured linear peptide (W(pG))3. MALDI-TOF
(m/z) [C48H47N9O7]: calcd, 860.3758; found, 884.3489 [M + Na + H]+.

Synthesis of Cyclic Peptide [W(pG)]3
The linear protected peptide sequence was assembled using H-Trp(Boc)-2chlorotrityl resin (0.51 g, 0.4 mmol, 0.78 mmol/g). The resin was swelled using DMF (3
× 30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp(Boc)OH and Fmoc-L-propargylglycine) and deprotection cycle with piperidine in DMF (20%
v/v). The final N-terminal Fmoc group was removed to assemble the sequence on the
peptidyl resin, NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl resin (Scheme
2). The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL) to remove any
traces of piperdine. Side chain-protected peptides were cleaved from the resins by
agitating the peptidyl resin with cleavage cocktail, acetic acid/ 2,2,2-trifluoroethanol
7

(TFE)/dichloromethane (1:2:7, v/v/v, 50 mL) for 1 h at room temperature followed by
filtration and washing the resin with TFE:DCM (2:8 v/v, 20 mL).
The collected filtrate was evaporated to reduce volume residue. Hexane (2 × 25
mL) and DCM (1 × 25 mL) were added to the residue to remove the acetic acid from the
residue. The solvents were evaporated to yield a fluffy white solid compound that was
dried overnight. The cyclization of the protected crude solid peptide was carried out in
the presence of a mixture of coupling reagents, 1-hydroxy-7-azabenzotriazole (HOAt)
(162 mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol) in
anhydrous DMF:DCM (60/200 mL) for 24 h.
The solvent was evaporated from a sample solution (5 mL) under reduced
pressure, and the residue was cleaved with reagent R that confirmed the cyclization by
mass spectrometry. Thus, all the solvents were removed under reduced pressure that
generated a high viscous liquid. The final peptide cleavage to remove the side chain
protection was carried out by shaking the residue with cleavage cocktail, reagent R,
TFA/thioanisole/anisole/EDT (90:5:2:3 v/v/v/v, 15 mL) for 2 h at room tempertuare. The
crude peptide was precipitated by the addition of cold diethyl ether (200 mL, Et 2O) and
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate.
The solid material was further washed with cold ether (2 × 100 mL). The crude peptide
was lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) as described
above to yield cyclic peptide [W(pG)]3. MALDI-TOF (m/z) [C48H45N9O6]: calcd,
843.3493; found 866.2380 [M + Na]+.
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Synthesis of Azide Functionalised Positively Charged Peptide (Ac-K(N3)R-NH2)
The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, FmocArg(Pbf)-OH and Fmoc-Lys(N3)-OH. The Rink amide resin was swelled with DCM (50
mL, 10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing
with DMF (3 × 30mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to
the peptidyl resin in the presence of coupling reagents HBTU (228 mg, 0.2 mmol/g) and
DIPEA (210 µL) in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at
room tempertuare for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min.
The Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25 mL, 2 ×
10 min) followed by washing with DMF (3 × 20 mL). The Fmoc-Lys (N3)-OH (173 mg,
0.2 mmol) was coupled by using HBTU (228 mg, 0.2 mmol), DIPEA (210 µL) in DMF
for 1 h. The resin was washed with DMF (3 × 20 mL), and Fmoc group was deprotected
by using piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed with
DMF followed by capping the amino group by acetic anhdyride (Ac2O, 95 µL, 1 mmol)
and DIPEA (174 µL, 1 mmol) in anhydrous DMF (3 mL) for 30 min. The resin was
washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried in vaccum overnight
before the final cleavage. A freshly prepared cleavage cocktail, TFA /triisopropylsilane
/water (95:2.5:2.5 v/v/v, 10 mL) was added to the resin and shaken at room temperature
for 1.5 h. The resin was filtered and evaporated to reduce the volume under dry nitrogen.
The crude peptide was precipitated by adding cold diethyl ether (200 mL, Et2O) and
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate.
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The peptide was purified by reversed-phase Hitachi HPLC using a gradient
system, and the HPLC fractions were collected, evaporated and lyophilized to obtain dry
product. ESI-TOF (m/z) [C14H27N9O3]: calcd, 369.2237; found, 370.2144 [M +H]+.

Synthesis of Amphiphilic Triazolyl Peptides by Click Chemistry of Peptides
(Linear or Cyclic) with an Azide-Functionalized Positively Charged Linear
Peptide
The click reaction was carried out in 20 mL glass vial with small magnetic stir bar
by adding the alkyne peptide (linear peptide (7.46 mg, 8.68 µmol) or cyclic peptide (7.25
mg, 8.68 µmol)), CuSO4.5H2O (6.5 mg, 0.026 mmole), Cu powder (16.5 mg, 0.26
mmol), sodium ascorbate (51.5 mg, 0.26 mmol), and azide-functionalized peptide, AcK(N3)R-NH2 (10 mg, 0.026 mmol) in methanol:water (2:1, 5 mL) followed by addition of
DIPEA (9 µL, 0.052 mmol). The mixture was stirred at room temperature for 24-48 h.
The completion of the reaction was confirmed by MALDI mass spectroscopy. The
reaction mixture was filtered, and the solvent was evaporated under reduced pressure to
afford the crude product. The crude product was further purified by HPLC using a
gradient system as described above, and the HPLC fractions were collected, evaporated
and lyophilized to obtain solid compounds. Linear-linear (WG(triazole-KR-NH2))3,
MALDI-TOF (m/z) [C90H128N36O16]: calcd, 1969.0309; found 1970.2032 [M + H]+;
Cyclic-linear [WG(triazole-KR-NH2)]3 MALDI-TOF (m/z) [C90H126N36O15]: calcd,
1951.0203; found 1951.6645 [M]+.
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Circular Dichroism
CD spectra were recorded on a JASCO J-810 spectropolarimeter using 1 mm path
length cuvettes. The scan speed was 100 nm/min, and spectra were averaged over 8
scans. All experiments on the samples including cyclic-linear [WG(triazole-KR-NH2)]3
and linear-linear (WG(triazole-KR-NH2))3 (1 mM, H2O) were tested at room temperature.
The CD for background reference (H2O) was measured and subtracted from the sample.

Transmission Electron Microscopy (TEM)
TEM analyses were conducted in JEOL Transmission Electron Microscope
(Tokyo, Japan) at an accelerating voltage 80 keV. The stock solution (1 mM) in deionized
water incubated for 3 days was used for the sample preparation. TEM samples of cycliclinear [WG(triazole-KR-NH2)]3 and linear-linear (WG(triazole-KR-NH2))3 were prepared
by depositing a droplet of 5 μL of 1 mM solution in H2O on a carbon-coated Cu support
grid of mesh size 300, which was allowed to rest for 2 min. After drop casting of peptide
solution, the grids were then stained with uranyl acetate (20 mL) for 2 min. Excess stain
was removed, and the grids were allowed to dry overnight.

Molecular Modeling
Cyclic-linear [WG(triazole-KR-NH2)]3 monomer was built using GaussView
software and completely optimized without any contraints utilizing Gaussian 03 software.
Charge density was plotted and colored according to electrostatic potential.
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Dynamic Light Scattering (DLS)
Zeta potential measurements were conducted by dynamic light scattering using a
Malvern Instruments Zetasizer Nano ZS (Worcestershire, UK). The machine was
calibrated using a 60 nm polystyrene standard. Each sample of (WG(triazole-KR-NH2))3
and [WG(triazole-KR-NH2)]3 (1 mL, of 1 mM) was loaded into a cell, and the particle
size and zeta potential were measured simultaneously in triplicate. To determine the size
distribution, 1 mL samples were placed in PCS1115 glass cuvettes and DLS was
performed at 25 °C at a backscatter angle of 173 with an equilibration time of 120 s. The
intensity was based on 11 scans.

Cell Culture
Ovarian adenocarcinoma SK-OV-3 and Human Embryonic Kidney 293 cells
HEK-293T cells obtained from American Type Culture Collection (ATCC no CRL11268). Cells were grown on 75 cm2 cell culture flasks with EMEM medium,
supplemented with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin
solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9 % NaCl) in a
humidified atmosphere of 5% CO2, 95% air at 37 ºC.

Cytotoxicity Assay
SK-OV-3 and HEK-293T cells were plated overnight in 96-well plates with
density of 5000 cells per well in 0.1 ml of appropriate medium at 37 ºC prior to the
experiment. The old medium (EMEM containing FBS (10%)) were replaced by different
12

concentrations of linear R3(WG)3 and cyclic R3[WG]3 peptides (5, 10, 15, 25, 50, 75,
100, 150 µM) in serum containing medium and incubated for 2 h at 37 °C in a humidified
atmosphere of 5% CO2. Similar experiments were conducted with linear (WG)3 and
cyclic [WG]3. Compounds were removed from medium by replacing with fresh medium,
and the cells were kept in an incubator for another 72 h. The cells without compounds
were incubated in each experiment as control. After 72 h, 20 µl of MTS was added to the
cell and incubated for 2 h. The absorbance of the formazan product was calculated with
the fluorescence intensity at 490 nm using a SpectraMax M2 microplate
spectrophotometer. The percentage of cell survival was calculated as [(OD value of cells
treated with the test mixture of compounds) − (OD value of culture medium)]/[(OD value
of control cells) − (OD value of culture medium)] × 100%.

3. Results and Discussion
Click chemistry has been previously used to design diverse structures of peptide
scaffolds. For instance, different derivatives of a triazole-containing kinase inhibitor
cyclo-[Pro-Val-Pro-Tyr]

peptide

were

synthesized

through

click

chemistry.20

Furthermore, triazoles were found to be an appropriate substituent for the amide bond in
peptides with a α-helical structure.21 Horne et al. designed a class of cyclic peptides
containing 1,4- or 1,5-disubstituted 1,2,3-triazoles22 that were found to serve as
surrogates for trans or cis amide bonds, respectively. Synthesis of amphiphilic peptides
containing hydrophobic and positively charged residues by click chemistry remains
unexplored. To the best of our knowledge, this is the first report of amphiphilic cycliclinear and linear-linear peptides linked through a triazole spacer.
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The synthesis of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3 peptides containing triazole rings were performed in two major
steps by synthesizing the building blocks containing alkyne and azide residues. First,
linear (W(pG))3 and cyclic [W(pG)]3 building block peptides (where (pG) =
propargylglycine) containing alkyne residues were synthesized by Fmoc-based chemistry.
Second, a building block containing azide residue, Ac-K(N3)R-NH2, was synthesized.
Finally, the building blocks were conjugated with each other through click chemistry. The
linear peptide (W(pG))3 was assembled on Rink amide resin (0.4 mmol, 0.68 mmol/g) by
solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-Trp(Boc)-OH and Fmoc-Lpropargylglycine (Scheme 1).
The peptide sequence was assembled on the resin followed by removing of the Nterminal Fmoc group to obtain the sequence NH2-(pG)W(Boc)(pG)W (Boc)(pG)W(Boc)Rink amide resin. The linear peptide was obtained after cleavage of peptidyl resin using
reagent R cleavage cocktail (trifluoroacetic acid (TFA)/thioanisole/ethanedithiol
(EDT)/anisole (90:5:3:2, v/v/v/v)) by shaking the mixture at room temperature for 2 h,
followed by precipitation with cold ether and centrifugation to afford solid crude linear
(W(pG))3 peptide, which was further purified by using HPLC.
In contrast with the synthetic procedure for the linear peptide, the cyclic peptide
[W(pG)]3 was synthesized by using H-Trp(Boc)-2-chlorotrityl resin (0.4 mmol, 0.78
mmol/g,) (Scheme 2). The resin was swelled using DMF followed by coupling and
deprotection cycles using appropriate amino acids and piperidine in DMF (20% v/v). The
final N-terminal Fmoc group was removed to assemble the sequence on the peptidyl
resin, NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl resin.
14

The side chain protected peptide was cleaved from the resin by agitating the resin
with cleavage cocktail, acetic acid/2,2,2-trifluoroethanol (TFE)/dichloromethane (1:2:7,
v/v/v) for 1 h at room temperature followed by filtration and evaporation of cocktail
liquid to afford the crude side chain protected peptide. The peptide was dried overnight
followed by N- to C-terminal cyclization by using coupling reagents, 1-hydroxy-7azabenzotriazole (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in DMF/DCM under
diluted conditions for overnight. The progress of the reaction was monitored by using
MALDI-TOF. The solvent was evaporated and Boc protecting groups were removed in
the presence of reagent R cleavage cocktail for 2 h followed by precipitation and HPLC
purification to afford the cyclic peptide.
The synthesis of azide-functionalized positively charged peptide building block
(Ac-K(N3)R-NH2) was performed on Rink amide resin (0.2 mmol, 0.68 mmol/g) using
building blocks of Fmoc-protected amino acids including Fmoc-Arg(pbf)-OH and FmocLys(N3)-OH. The resin was swelled and deprotected to couple arginine followed by
deprotection and coupling with Fmoc-Lys(N3)-OH. The Fmoc group was deprotected,
and amino group was further capped using acetic anhydride in DMF. The peptide was
cleaved from the resin using a cleavage cocktail containing TFA/TIS/H2O (95:2.5:2.5,
v/v/v) and purified by HPLC to afford Ac-K(N3)R-NH2 (Scheme 3).
Finally, the linear-linear and cyclic-linear amphiphilic triazolyl peptides were
synthesized by click reaction between the linear or cyclic peptides containing alkyne,
(W(pG))3 and [W(pG)]3, and azide-functionalized linear peptide Ac-K(N3)R-NH2 in
solution phase using CuSO4.5H2O, Cu powder, sodium ascorbate, and N,Ndiisopropylethylamine (DIPEA) in methanol/water for 24-48 h (Scheme 4).
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The azide peptide Ac-K(N3)R-NH2 was used in excess (more than 3 equiv) to
conjugate with the three alkyne functional groups in the linear or cyclic peptides at room
temperature and afford the linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3 in 33-35% yield (Scheme 5). The formation of the conjugated
1,4 product was confirmed by MALDI-TOF mass spectroscopy. The structure of
optimized conformation of cyclic-linear [WG(triazole-KR-NH2)]3 monomer was
evaluated for charge distribution. The modeling exhibited positively charged arginine
extending out of the cyclic peptide (Figure 1). The secondary structure of peptides is one
of the responsible elements in the self-assembly pattern.
Circular dichroism (CD) was employed to obtain insights about the secondary
structure of both peptides. The secondary structures of the majority of peptides are
divided into three major classic forms namely β-sheet, α-helix, and random coil. The βsheet structures get stabilized through available hydrogen bonding between oligopeptide
strands. However, intra-chain hydrogen bonds help the α-helix to form a stable coiled
structure. The CD results showed that both peptides have a relatively similar structure.
CD spectra of the cyclic-linear peptide (1 mM) solution in water at room temperature
showed two minima peaks at 226 nm and 199 nm. The linear peptide exhibited a similar
CD pattern to the cyclic peptidewith two minima peaks at 226 nm and 202 nm (Figure 2).
However, a blue shift from 202 to 199 nm was found for the cyclic peptide as compared
to the linear, suggesting that the secondary structure of the cyclic peptide is slightly
different. A distinct α-helix structure shows two minima peaks at 222 and 208 nm. Thus,
the structures of these peptides did not follow a typical α-helical structure.
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The size and morphologies of peptide nanoparticles were monitored by using
transmission electron microscopy (TEM). As shown in Figure 3, the cyclic-linear
[WG(triazole-KR-NH2)]3 formed spherical nanostructures in the size range of 50-80 nm.
However, the linear-linear (WG(triazole-KR-NH2))3 exhibited entirely different
morphologies and size compared to that of the cyclic-linear counterpart. The linear
peptide showed nanosized network with particles as small as 5-10 nm. Small sized
particles showed aggregation by forming larger particles in the size range 50-100 nm
(Figure 4). DLS studies showed a monodisperse size distribution for both linear-linear
(WG(triazole-KR-NH2))3 and cyclic-linear [WG(triazole-KR-NH2)]3 while the latter
showed larger nanoparticles (Figures 5 and 6).
Although linear-linear and cyclic-linear peptides share the equal number of
similar amino acids, they form different types of particles presumably because of the
difference in the orientation of positively charged guanidine groups in arginine and
hydrophobic tryptophan residues.
Cytotoxicity of both linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3 peptides were evaluated in SK-OV-3 and HEK-293T cells
(Figures 7 and 8). In general, the peptides did not show significant toxicity at
concentration of <25 µM in HEK-293T cells. While cyclic-linear [WG(triazole-KRNH2)]3 did not exhibit any significant toxicity in SK-OV-3 cells at a concentration of 75
µM, linear-linear (WG(triazole-KR-NH2))3 reduced the cell proliferation by 20% at this
concentration. Similar results were obtained when comparing linear (W(pG))3 (Figure 9)
and cyclic [W(pG)]3 (Figure 10) building blocks, showing the cyclic peptide less
cytotoxic than the linear counterpart.
17

4. Conclusion
In conclusion, a new class of amphiphilic peptides containing arginine and
tryptophan, linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear [WG(triazole-KRNH2)]3, was synthesized by using click chemistry. CD spectroscopy exhibited that the
secondary structures of both peptides have a similar pattern. Cyclic-linear [WG]3 and
linear-linear (WG)3 showed nano-sized structures in a range size of 50-100 nm.
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Figure Legends:

Figure 1. Molecular electrostatic potential surface of [WG(triazole-KR-NH2)]3.
Figure 2. CD spectra of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3.
Figure 3. TEM images of cyclic-linear [WG(triazole-KR-NH2)]3.
Figure 4. TEM images of linear-linear (WG(triazole-KR-NH2))3.
Figure 5. Dynamic light scattering (DLS) of linear-linear (WG(triazole-KR-NH2))3.
Figure 6. Dynamic light scattering (DLS) of cyclic-linear [WG(triazole-KR-NH2)]3.
Figure 7. Cytotoxicity of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3 in HEK-293T cells after 2 h.
Figure 8. Cytotoxicity of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3 in SK-OV-3 cells after 2 h.
Figure 9. Cytotoxicity of linear (WG)3 in SK-OV-3 cells after 2 h.
Figure 10. Cytotoxicity of cyclic [WG]3 in SK-OV-3 cells after 2 h.
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Scheme Legends:
Scheme 1. Synthesis of linear (W(pG))3 as the building block.
Scheme 2. Synthesis of cyclic [W(pG)]3 as the building block.
Scheme 3. Synthesis of positively charged peptide containing azide as the building
block.
Scheme 4. Synthesis of linear- linear (WG(triazole-KR-NH2))3 and cyclic-linear
[WG(triazole-KR-NH2)]3.
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Abstract
The objective of this study was to understand the differential behavior of nanostructures
formed by cyclic peptides containing tryptophan and arginine residues at the molecular
level. [WR]4 was reported to be effective in enhancing cellular delivery of a number of
drugs, such as lamivudine (2′,3′-dideoxy-3′-thiacytidine, 3TC) and dasatinib while
[WG(triazole-KR-NH2)]3 was found to be an inefficient molecular transporter. Ab initio
molecular orbital calculations coupled with molecular dynamics simulation studies along
with experimental results showed that nanostructure formation by these cyclic peptides
were induced by counterions. Our results showed the suitability of [WR]4 system in
enhancing the delivery of fluorescence-labeled drugs (e.g., fluorescence-labeled 3TC (F′3TC) and fluorescence-labeled daststinib (F′-Das)) were consistent with the experimental
results. The conformational flexibility, charge environment, and hydrophilic-lipophilic
balance (HLB) of these peptides were found to play important roles in determining their
drug delivery capabilities.
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Introduction

Bioorganic peptide nanostructure refers to a synthetic peptide molecule that can
spontaneously self-assemble to form structures of diameter up to 50 nm. Such selfassembled structures have drawn the attention of scientists in diverse fields due to
attractive applications in medicine, material science, biotechnology, and nanotechnology
based devices.1-6 These self-assembled structures are largely held together by noncovalent interactions like hydrogen bonding, electrostatic interactions, and hydrophobic
interactions.7-9 Self-assembling systems have conventionally been of interest to scientists
requiring different types of ecofriendly biosurfactants for membrane stabilization.
Peptides surfactants, or pepfactants, have emerged as interesting alternatives
forming dynamic nanostructures in pure solution. Cyclic peptides with amphiphilic
groups are more stable as compared to their linear counterparts but have remained less
studied due to their synthetic complexities.10 We have recently reported on some
amphiphilic cyclic L-peptides forming spontaneous nanostructures acting as stabilizing
agents for silver nanoparticles and proteins.11 Self-aggregation of biosurfactants in the
bulk aqueous phase forms different shapes like spherical, bilayer, or cylindrical
depending on hydrophilic-lipophilic balance (HLB). It is known that short amphiphilic
peptides containing 10–30 amino acid residues (mostly cationic residues like arginine or
lysine) possess the ability to penetrate the cell membrane.12-15 These cell-penetrating
peptides (also referred to as CPPs) have been successfully utilized to deliver a large
number of macromolecules like proteins, oligonucleotides, and polysaccharides
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intracellularly without causing significant toxicity.16-25 CPPs can exert their effect in
vitro and in vivo in micromolar concentrations.26
We have reported 27-fold enhancement in the cellular uptake of fluorescencelabelled phosphopeptide F'-PEpYLGLD in presence of 50 µΜ solution of cyclic peptide
[WR]4 (Figure 1) containing tryptophan and arginine residues.27 Isothermal calorimetry
studies confirmed the interaction between the cyclic peptide carrier and the negatively
charged cargo phosphopeptides. We have recently designed and reported amphiphilic
triazolyl peptides (Scheme 1) synthesized from peptide building blocks containing alkyne
and azide functional groups. Cyclic [W(pG)]3 (containing alkyne) (where (pG) =
propargylglycine) was conjugated with a peptide functionalized with azide group, AcK(N3)R-NH2, through click chemistry to afford cyclic-linear [WG(triazole-KR-NH2)]3
peptide (Figure 1).28 The resulting cyclic-linear peptide formed nanostructures and was
compared as a drug delivery system with [WR]4.
In the present work, we report on the structural and dynamical aspects of these
nanostructures and how these properties govern their drug delivery capabilities. We
investigated how the morphology of these systems can be tuned to attain desired
nanostructures with desired drug delivery capabilities. Ab initio molecular orbital
calculations were used in conjunction with intermolecular interaction studies and
molecular dynamics simulations.
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Methods
Ab initio molecular orbital calculations 29, with complete geometry optimizations,
were performed at the Hartree Fock level utilizing CEP-31G 30 basis set for the monomer
cyclic peptides. Geometry optimizations were performed utilizing Berny’s gradient
method.31,32 Self-assembly was explored step by step to determine the possibility of
dimer formation, trimer, tetramer, respectively, by repeated interaction energy
calculations. Every time a monomer is added interaction energy was calculated as
Interaction energy = Ecomplex of n monomers – (n. Emonomer)
In this case since the monomers are cationic and repel each other in the absence of
counterions, this is the energy consumed in nanoparticulate formation in the absence of
counter ions. In the presence of counter ions, energy released in nanoparticulate
formation is given as
Interaction energy = Ecomplex of n monomers and m counterions – (n. Emonomer + m Ecounterion)
Different possibilities of self-assembly were considered, such as tubular, film
formation, and spherical nanoparticulate formation in presence and absence of
counterions. Self-aggregation and nanostructure formation were considered in the
presence of inducing trifluoroacetate counterions present under experimental conditions.
Trifluoroacetic acid (TFA) (2%) was added to water and acetonitrile for HPLC
purification.

44

These calculations were carried out using GAUSSIAN ’0933 software and
GAUSSVIEW34 was used for viewing purposes. After nanostructure formation, its role
as drug delivery system was investigated through molecular dynamics simulations. First
the cargo drug was docked inside the nanostructure manually. The stability of this loaded
nanostructure with time and its dynamical behavior were then studied utilizing molecular
dynamics simulation. The containment of drug for a period followed by its delivery was
also studied through simulations.
The self-aggregated nanostructure in presence of counterions with drug loaded in
core was subjected to relaxation prior to molecular dynamics simulations. System was
then subjected to simulated annealing followed by long dynamics at 300K. Shaw’s
Desmond software35, was utilized for the purpose using OPLS force field.36 NPT
(isothermal-isobaric) ensemble was taken using Martyna-Tobias-Klein barostat method.37
Reversible reference system propagator algorithms (RESPA integrator) was used with 2
fs time step for near and bonded atoms and 6 fs time step for far atoms.38 Coulombic
interaction cutoff was set at 9.0 A. 3.0 ns trajectory was evaluated in each case. Energy
analysis and RMSD analysis for all heavy atoms are presented to judge the stability of the
system with time. RMSD was taken with reference to frame zero after relaxation of the
system.

45

Cell-based Assays
Cell Culture
Human leukemia cells (CCRF-CEM, ATCC no. CCL-119) were purchased
obtained from American Type Culture Collection. Cells were cultured in 75 cm2 flasks
containing RPMI-16 medium. The medium contains supplemental, such as fetal bovine
serum (FBS, 10%) as well as penicillin-streptomycin (penicillin: 1%, 10 000 units and
streptomycin: 10 mg in 0.9% NaCl) that were used under humidified atmosphere
balancing CO2 (5%) and air (95%) at 37 °C.

Flow Cytometry Studies
CCRF-CEM cells (1 × 107/well) were plated in 6-well plates. Fluorescencelabeled dasatinib (F´-Das) was used as a model drug for this comparative experiment.
Thus, F´-Das (5 μM) was added alone and in combination with [WR]411b

and

[WG(triazole-KR-NH2)]3 28 into wells. All experiments were carried out in triplicate. All
plates were kept at 37 °C for 2 h. In this assay, cells with no treatment with F´-Das were
employed as negative controls. The treatments were removed after 2 h of incubation. To
wash the cell membrane surface, trypsin−EDTA solution was used for 5 min. After that,
the cells were twice washed with PBS (5 min each time). To prepare cells for analysis,
they were resuspended in flow cytometry buffer and filtered. The analysis of the
experiment was performed by FACSVerse flow cytometer using FITC channel. The data
for each entry was acquired based on the signal mean fluorescence in 10,000 cells.
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All assays were performed in triplicate. A similar procedure was used for flow
cytometry studies of the fluorescence-labeled 3TC (F′-3TC) in the presence of the
peptides.

Results and Discussion
We have previously shown that peptides containing amino acids with
hydrophobic and positively charged residues can form nanostructures at room
temperature.11 The presence of optimized balance between hydrophobicity and charge
was determined to be a major driving force for the formation of self-assembled
nanostructures through inter and intramolecular interactions.
Initial TEM imaging of [WR]4 showed that this peptide forms nano-spherical
particles with the size of 70-85 nm. Multiple forces could be responsible in forming
nanosized structure. Hydrophobic segments of the peptide can trigger the supramolecular
self-assembly and force the peptide to generate nanospherical structures. Furthermore,
TEM investigations on size and morphologies of [WG(triazole-KR-NH2)]3 showed that
this peptide can also form spherical structures in the size range of 50-80 nm in aqueous
media (Figure 2). Several factors can be involved in the formation of such a structure,
including hydrogen bonding and hydrophobic forces.28 TEM observation revealed that
although the structure of [WG(triazole-KR-NH2)]3 and [WR]4 are different, they
generated nanoparticles with similar size range and morphologies. Chemical structure of
[WG(triazole-KR-NH2)]3 represents a higher degree of flexibility in arginine side chains
compared to that of [WR]4.
47

However, existence of triazole rings could also induce some degree of rigidity to
the structure of [WG(triazole-KR-NH2)]3. These data suggest that the orientation of amino
acids, such as tryptophan and arginine, can determine the size and morphologies of
nanostructures.
Cyclic peptide containing tryptophan and arginine [WR]4 and the amphiphilic
triazolyl cyclic-linear peptide [WG(triazole-KR-NH2)]3 were completely optimized
utilizing ab initio Hartree Fock molecular orbital calculations at the CEP-31G level. The
structures of these systems along with their optimized conformations are shown in Figure
1. The molecular electrostatic potential surfaces for both systems are shown in Figure 3.
Both systems are cationic in nature, and the data clearly indicate that they require
inducing counterions for self-aggregation. However, this became more obvious on a
detailed examination of the differences in the potential surfaces of both systems.
In [WG(triazole-KR-NH2)]3 system, the positive charge is located at the ends of
the long KR-NH2 side chains; whereas in [WR]4 system the positive charge is delocalized
over the entire system. Because of these differences, the location of counterions in both
systems is quite different resulting in a more compact spherical aggregated form in
[WR]4 that is more stable. The experimental procedure for purification of both peptides
required the use of trifluoroacetate (TFA). Thus, TFA ions were present as the
counterions. Considering the availability of these ions, ab initio intermolecular interaction
calculations were performed to study counterion-induced self-aggregation of these
systems.
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As mentioned earlier, self-aggregation may be in different shapes. Therefore, we
examined multiple shapes relevant to explain the behavior of these systems at lipid
membrane interface and their molecular transporter properties.

Results for self-

aggregation of cyclic peptide [WR]4 and cyclic-linear peptide [WG(triazole-KR-NH2)]3
are shown in Figures 4 and 5, respectively. Both systems showed formation of spherical
nanoparticulates suitable for drug carriage and delivery. The linear or tubular stacking
does not generate an inner core sufficiently large enough for the carriage of drugs or
molecules. The monomer conformations of cyclic peptides under consideration are not
appropriate for tubular structure formation. Overall charge neutrality was maintained in
the aggregated form to enable us to study the dynamical behavior utilizing simulation
studies. The nanostructure formed by [WR]4 system has the dimensions 7.2 nm x 6.9 nm
x 2.0 nm while the nanostructure formed by [WG(triazole-KR-NH2)]3 system has the
dimensions 12.0 nm x 10.6 nm x 3.2 nm. These dimensions may vary with variations in
aggregated forms but are indicative that the aggregated forms lie in the range of
nanostructure.
To compare the transporting ability of [WG(triazole-KR-NH2)]3 and [WR]4, a
flow cytometry assay was carried out. Fluorescence-labeled dasatinib (F'-Das) was
employed as a model molecular cargo. The intracellular uptake of F'-Das was evaluated
in the presence of [WG(triazole-KR-NH2)]3 and [WR]4 and compared with that of the
drug alone. As it is shown in Figure 6, the presence of [WR]4 enhanced the cellular
uptake of F'-Das by 2.5 fold compared to that of F'-Das alone. However, the results
showed that the intracellular uptake of F'-Das was not enhanced in the presence of
[WG(triazole-KR-NH2)]3. These data indicated that although both peptides contain
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tryptophan and arginine amino acids, they have different transporting abilities for the
delivery of F'-Das due to other factors.
Moreover, the intracellular transporting potency of [WR]4 and [WG(triazole-KRNH2)]3 were compared by using lamivudine (3TC), an anti-HIV drug. The fluorescencelabeled 3TC was prepared based on our previously reported procedure.11 As expected,
the flow cytometry results showed that the cellular uptake of F´-3TC (5 µM) was
increased by more than 3-fold when mixed with [WR]4 (50 µM). However, uptake of F´3TC was reduced in the presence of [WG(triazole-KR-NH2)]3. These data confirmed that
[WR]4 is a molecular transporter while

[WG(triazole-KR-NH2)]3 is inefficient in

improving the cellular delivery.
Molecular modeling and ab intio intermolecular interaction calculation were used
to explain the differential behavior of these two cyclic peptides as molecular transporters.
The drugs were loaded inside nanostructure to study their carriage and delivery by the
peptides. Figures 7 and 8 shows a comparison of solvation energy of fluorescence-labeled
3TC (F′-3TC) and dasatinib and stabilization of drugs inside the nanostructures formed
by the two cyclic peptides.
The stabilization of drug inside nanostructures clearly indicates why the drug will
be spontaneously encapsulated by the peptides. Figure 9 shows a comparison of solvation
energy of fluorescence-labeled dasatinib (F′-Das) and its stabilization inside the
nanostructures formed by cyclic peptides. In this case, stabilization offered by peptide
nanostructures indicates spontaneous encapsulation of drug. It is also to be noted that the
stabilization of drug inside the nanostructure formed by [WG(triazole-KR-NH2)]3 system
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is lower than that of [WR]4. This is due to overall lower charge on [WG(triazole-KRNH2)]3 resulting in less number of counterions and less compact nanostructure due to
monomer conformation.
The stability of encapsulated drug and chances of premature expulsion were
studied by molecular dynamics simulation studies by evaluating 3ns trajectory. The
results for carriage of both the drugs by [WR]4 peptide nanostructure are shown in Figure
10. Snapshot of system during relaxation and root mean square deviations (RMSD) of all
heavy atoms throughout simulation are also shown in Figure 10. The RMSD plot clearly
shows a reduction in mobility of peptide monomers on nanostructure formation with
trifuoroacetate counterions and after loading nanostructure with F′-3TC as well.
Encapsulation of F′-Das leads to some instability perhaps due to the larger size of the
drug.
Carriage of fluorescence-labeled anti-HIV drug F′-3TC and anticancer drug F′-Das
by [WG(triazole-KR-NH2)]3 nanostructure are shown in Figure 11. Snapshots of relaxed
system during simulation show a very loosely held nanostructure which has opened up to
some extent depicting probability of premature expulsion of both the drugs. Moreover,
noticeable is the significant change in monomer conformations with folded (KR-NH2)
side chains. The flexible side chains of this peptide have folded to maximize electrostatic
interactions with TFA and intramolecular H-bonding as opposed to interactions with the
drug.
This is in contrast to the encapsulation of these drugs by [WR]4 nanostructure
which maximizes interactions with drugs to form a compact loaded nanostructure. The
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HLB of this system also seems to play a critical role in this reorganization leading to
loosely held nanostructures inappropriate for drug delivery. RMSD shows little effect of
drug loading perhaps due to opening of nanostructure and expulsion of the drug at the
time of relaxation itself during initial stages of the simulation.
This study depicts the suitability of cyclic peptide [WR]4 nanostructures in
enhancing the bioavailability of anti-HIV and anticancer drugs of appropriate size.
However, cyclic peptides containing cell permeability enhancing arginine residues, but
with high mobility of side chains are found to be unsuitable for delivery purposes.

Conclusions
In this study, we have presented ab initio molecular orbital calculations coupled
with molecular dynamics simulation studies to show how cyclic amphiphilic peptide
[WR]4 forms nanostructures by self aggregation induced by counterions and enhances the
cellular delivery of certain nuclear targeted anticancer agents. We have also shown that in
[WG(triazole-KR-NH2)]3 the cargo-loaded nanostructures were not stable, leading to
premature expulsion of the drug and no significant enhancement in cellular delivery. The
conformational flexibility of cyclic peptides, their charge environment, and HLB ratio all
play important roles in governing the self-aggregation and molecular transporter
properties of these amphiphilic cyclic peptides. Molecular dynamics simulation results
confirm the experimental cellular assay observations.
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Figure Legends:

Figure 1. TEM images of [WG(triazole-KR-NH2)]3 (a,b) and [WR]4 (c,d).
Figure 2. Molecular electrostatic potential surfaces of cyclic peptides.
Figure 3. Self-aggregation of [WR]4.
Figure 4. Self-aggregation of [WG(triazole-KR-NH2)]3.
Figure 5. Cellular uptake of F'-Das in the presence of [WR]4 and [WG(triazole-KRNH2)]3.
Figure 6. Cellular uptake of F'-3TC in the presence of [WR]4 and [WG(triazole-KRNH2)]3.
Figure 7. Comparison between stabilization of F′-3TC in aqueous solution and
stabilization inside peptide nanostructures of [WG(triazole-KR-NH2)]3.
Figure 8. Comparison between stabilization of fluorescein-labeled dasatinib in
aqueous solution and stabilization inside peptide [WG(triazole-KR-NH2)]3
nanostructure.
Figure 9. Carriage of fluorescein labeled lamivudine by [WR]4 nanostructure.
Figure 10. Carriage of fluorescein-labeled dasatinib by peptide [WG(triazole-KRNH2)]3.
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Figure 2.
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Figure 3.

Length ~ 7.2 nm
Breadth ~ 6.9 nm
Height ~2.0 nm

Interaction energy= -2806.14 kCal/mol

Interaction energy= -1212.93 kCal/mol
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Figure 4.

Length ~ 12.0 nm
Breadth ~10.6 nm
Height ~ 3.2 nm

Interaction energy= -1,470.93 kCal/mol

Interaction energy= -1,648.37 kCal/mol
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Figure 5.
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Figure 6.
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Figure 7.
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Figure 8.
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Figure 9.
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Figure 10.
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Scheme Legends:

Scheme 1. Structures and optimized conformations of cyclic amphiphilic peptides
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Scheme 1.

[WR]4

[WG(triazole-KR-NH2 )]3
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Abstract

Three classes of amphiphilic peptides were synthesized and evaluated as molecular
transporters and/or antibacterial agents. Herein we describe the details of the synthesis of
the compounds using click chemistry or amide conjugation. The three classes include (a)
cyclic-linear

[WG(triazol-KR-NH2)]4

and

linear-linear

(WG(triazol-KR-NH2))4

conjugated through a triazolyl linker, (b) cyclic-linear [WG(AC-KR-NH2)]3 and linearlinear (WE(AC-KR-NH2))3 conjugated through an amide linker, and (c) fatty acyl
triazolyl peptides containing myristoyl and stearoyl substituents. The syntheses were
accomplished through solid-phase methods followed by click chemistry or amide
formation to install the arginine side chains and fatty acyl groups, respectively.
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Introduction
Enhanced translocation of drug compounds across plasma membranes is an
important strategy to reduce the administered dose and subsequently the side effects of
drugs. Among the cell-penetrating peptides (CPPs), arginine-rich peptides have been
studied widely and gained much attention due to their efficiency, simplicity, and aqueous
solubility.1 Cationic residues in CPPs, particularly the guanidine moiety in arginine-rich
peptides, have been known to play a crucial role for the membrane translocation
capability.2,3
The critical role of arginine residues in the interaction of CPPs with cell
membranes has been described previously by systematic replacement of arginine residues
with alanine residues. Such substitutions induced a strong reduction of peptide uptake
that was correlated with the number of substituted arginine residues. Thus, the central
structural scaffold of the peptides required for cellular uptake was the guanidine head
group of arginine.4 Several studies on the binding affinities of cationic cell penetrating
peptides indicate that CPPs strongly bind electrostatically to the negative charges on the
cell membranes, including lipid head groups, proteins like nucleolin, and proteoglycans
such as heparin sulfate.5,6 Although electrostatic interactions are known to be important
for

arginine-rich

cell-penetrating

peptides,

non-electrostatic

effects

such

as

hydrophobicity and peptide structural transitions can also contribute to the binding
affinity of amphiphilic cell-penetrating peptides to cell membranes.7
The successful therapeutic strategies using CCPs has been limited by the poor
delivery efficiency of existing synthesized amphiphilic peptides. The development of
alternative modified peptides for improved delivery of therapeutic agents and enhanced
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biological activity is needed urgently. Parang and coworkers have discovered a new class
of amphiphilic peptides, namely [WR]4 that showed the ability to translocate across the
cell membrane. Both the positively charged residues and hydrophobic tryptophan
contributed in enhancing the cellular uptake property of [WR]4. Fluorescence activated
cell sorting (FACS) analysis showed that the cellular uptake of F′-PEpYLGLD in the
presence of [WR]4 was increased by 27-fold when compared to F′-PEpYLGLD alone.8
Amphiphilic peptides have also become attractive and received attention as
potential antibacterial agents. Antimicrobial peptides (AMPs) are produced in nature and
are considered the first line of host defense protecting living organisms from pathogenic
microorganisms. AMPs are produced at low levels in multi-cellular organisms.9
Synthetic amphiphilic peptides have been shown to possess a broad spectrum of
antitumor, antiviral, and antifungal activities.10,11 The mechanism of action of
antimicrobial peptides involves a non-receptor mediated mechanism whereby the
compounds directly target the lipid membrane of the cells.12 All AMPs tend to share
some common characteristics, such as having amphipathic structure containing both
hydrophilic and hydrophobic residues that allow binding to the hydrophilic and
hydrophobic core of the membrane.13
AMPs have nonselective binding since they cannot differentiate between
prokaryotic and eukaryotic cells based on hydrophobicity.14 All AMPs consist of high
number of cationic amino acids that result in net positive charge on the peptides, which
will bind to the anionic lipids in the bacterial membrane.15 It has been reported that
reducing the positive charge of peptides will lower the activity and subsequently the
selectivity of AMPs.16,17
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Parang et al. (2014) recently reported the synthesis of amphiphilic cyclic CPPs,
such as [R4W4] that exhibited potent activity against methicillin-resistant Staphylococcus
aureus (MRSA) with a minimum inhibitory concentration (MIC) of 2.67 µg/mL.18
It has been previously reported that addition of fatty acids tail connected to the
AMPs can enhance both the activity and selectivity of the peptides

19,20

Matthew and his

co-workers reported that conjugation of fatty acid to the AMPs led to increased
antibacterial activity of amphiphilic peptides.21 A new class of peptide amphiphilic (PAs)
containing positive charged peptide conjugated with fatty acyl chains showed significant
improvement in delivery of different cargo molecules.22 Studies on the antimicrobial
peptide lactoferrin showed that peptide conjugated with twelve carbon fatty acid was able
to improve the activity and selectivity of peptide.23 Other groups have reported that
AMPs conjugated to fatty acids with different length ranging from 12 to 18 methylene
units improved the activity and selectivity of peptide.24
The Parang group recently reported the synthesis of four amphiphilic peptides
containing positive charge, namely on arginine and lysine residues, conjugated with C14palmitic acid and C16- myristic acid.23 Furthermore, Parang’s laboratory synthesized and
evaluated fatty acylated cyclic polyarginine peptides (ACPPs), such as octanoyl[KRRRRR], dodecanoyl-[KRRRRR], and hexadecanoyl-[KRRRRR] as antibacterial
agents. All fatty acylated cyclic peptides exhibited more potent antibacterial activity than
the non-acylated cyclic peptide [R]5.18
Efficient intracellular delivery of biological cargos and/ or improving antibacterial
activity requires systematic design of amphiphilic peptides with sufficient number of
positively charged amino acids and hydrophobic residues. In continuation of our efforts
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to design improved amphiphilic peptides, three class of peptides were synthesized: (1)
Modified amphiphilic triazolyl cyclic-linear and linear-linear peptides; (2) Amphiphilic
peptide amide derivatives (APADs); and (3) Amphiphilic fatty acyl triazolyl peptides
(Figure 1).
The first section of this chapter describes the synthesis of the modified
amphiphilic triazolyl peptides (ATPs) using Fmoc solid phase peptides synthesis. The
peptides incorporate an increased number of propargyl glycine (pG) and tryptophan (W)
residues. The peptides were then conjugated using click chemistry with arginine-lysine
(R-K) peptides containing an azide linker to form cyclic-linear [WG(triazol-KR-NH2)]4
and linear-linear (WG(triazol-KR-NH2))4 amphiphilic triazolyl peptides. The biological
and physicochemical properties of these peptides will be evaluated and compared with
the previously synthesized peptides described in Chapter 2.
The second section of this chapter describes the synthesis of Amphiphilic Peptide
Amide Derivatives (APADs). The goal was to compare APADs with the Amphiphilic
Triazolyl Peptides (ATPs) described in Chapter 1. APADs with amide bond are presumed
to interact with the membrane with more flexibility compared with rigid triazolyl ring of
ATPs. By applying Fmoc-based peptide chemistry, APADs were synthesized by coupling
of tryptophan (W) residues and glutamic acid (E) with different sequence length. The
linear and cyclic peptides were conjugated to arginine lysine (R-K) residues through
amide bond. The biological and physicochemical properties of APADS will be evaluated
and compared with ATP in future.
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Finally, the third group of amphiphilic fatty acyl triazolyl peptides was
synthesized as potential antibacterial agents. These peptides consist of fatty acids with
different chain lengths of 14 and 18 carbons. We hypothesized that a new class of
Amphiphilic Fatty Acyl Triazolyl Peptides (AFTP) with different acyl chain lengths
could provide novel antibacterial agents. Two fatty acyl derivatives (myristoyl and
stearoyl) were synthesized in this class. Stearic and myristic acids were conjugated with a
positively charged peptide containing azide using the click reaction. Their
characterization and antibacterial activity for these compounds will be evaluated in the
future.
Experimental Section
General
All reactions were carried out in Bio-Rad polypropylene columns by shaking and
mixing in Glass-Col small tube rotator under dry conditions at room temperature unless
otherwise stated. In general, all peptides in Class I were synthesized and characterized as
described in chapter 1. All peptides were synthesized using solid-phase techniques.
commercially available Fmoc amino acids, resins were purchased from Sigma-Aldrich
Chemical Co. (Milwaukee, WI). The crude peptides were purified by using a reversedphase Hitachi HPLC (L-2455) on a Gemini C18 column (250 mm × 21.20 cm, 10 µm)
and a gradient system. The peptides were separated by eluting the crude peptides at 10.0
mL/min using a gradient of 0-100% acetonitrile (0.1% trifluoroacetic acid (TFA)) and
water (0.1% TFA) over 60 min, and then were lyophilized.
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Synthesis of Linear-Linear (WG(triazole-KR-NH2))4 and Cyclic-Linear
[WG(triazole-KR-NH2)]4

Synthesis of Linear Peptide (WpG)4
The linear peptide was assembled on Rink amide resin (0.59 g, 0.4 mmol, 0.68
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected
amino acids [Fmoc-Trp(Boc)-OH and Fmoc-L-propargylglycine] (Scheme 1). The linear
peptide sequence was assembled on the resin after removing the Fmoc group at the Nterminal in the presence of 20% piperidine in DMF (20% v/v) to obtain the sequence
NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-Rink amide resin. The resin was
washed with DMF/DCM and dried under vacuum for 24 h. Reagent R cocktail containing
trifluoroacetic acid (TFA)/thioanisole/ethandithiol (EDT)/ anisole (90:5:3:2 v/v/v/v, 20.2
mL) was used to cleave the peptide from the resin. The crude peptide was precipitated by
adding the filtrates to cold diethyl ether (200 mL, Et2O). The solution was centrifuged at
4000 rpm for 5 min followed by decantation to obtain the solid precipitate. The peptide
was lyophilized and purified by reversed-phase HPLC using a gradient system as
described above to yield solid white coloured linear peptide (W(pG))4 (Scheme 1).
MALDI-TOF (m/z) [C64H62N12O9]: calcd, 1142.4763 ; found, 1143.3317 [M + H]+,
1181.3810 [M + K]+.

Synthesis of Cyclic Peptide [W(pG)]4
The linear protected peptide sequence was assembled using H-Trp(Boc)-2chlorotrityl resin (0.51 g, 0.4 mmol, 0.78 mmol/g). The resin was swelled using DMF (3
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× 30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp(Boc)OH and Fmoc-L-propargylglycine) and deprotection with piperidine in DMF (20% v/v).
The final N-terminal Fmoc group was removed to assemble the sequence on the peptidyl
resin,

NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl

resin

(Scheme 2). The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL) to
remove any traces of piperdine. Side chain-protected peptides were cleaved from the
resins by agitating the peptidyl resin with the cleavage cocktail, acetic acid/ 2,2,2trifluoroethanol (TFE)/dichloromethane (1:2:7, v/v/v, 50 mL), for 1 h at room
temperature followed by filtration and washing the resin with TFE:DCM (2:8 v/v, 20
mL). The collected filtrate was evaporated to reduce the volume. Hexane (2 × 25 mL)
and DCM (1 × 25 mL) were added to the residue to remove the acetic acid. The solvents
were evaporated to yield a fluffy white solid compound that was dried overnight under
vacuum. The cyclization of the protected crude solid peptide was carried out in the
presence of a mixture of coupling reagents, 1-hydroxy-7-azabenzotriazole (HOAt) (162
mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol), in
anhydrous DMF:DCM (60/200 mL) for 24 h. The solvent was evaporated under reduced
pressure and the residue was deprotected with reagent R. The cyclization was confirmed
by mass spectrometry.

All the solvents were removed under reduced pressure that

generated a high viscous liquid.
The final peptide cleavage to remove the side chain protection was carried out by
shaking the residue with cleavage cocktail, reagent R, TFA/thioanisole/anisole/EDT
(90:5:2:3 v/v/v/v, 15 mL), for 2 h at room temperture. The crude peptide was precipitated
by the addition of cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm for 5
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min followed by decantation to obtain the solid precipitate. The solid material was further
washed with cold ether (2 × 100 mL). The crude peptide was lyophilized and purified by
reversed-phase HPLC as described above to yield cyclic peptide [W(pG)]4 (Scheme 2).
MALDI-TOF (m/z) [C64H60N12O8]: calcd, 1124.4657; found 1147.3156 [M + Na]+ ,
1163.3579 [M + K]+.

Synthesis of Azide Functionalized Positively Charged Peptide (Ac-K(N3)R-NH2)
The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, FmocArg(Pbf)-OH and Fmoc-Lys(N3)-OH. The Rink amide resin was swelled with DCM (50
mL, 10 min) followed by DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing
with DMF (3 × 30 mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to
the peptidyl resin in the presence of coupling reagents HBTU (228 mg, 0.2 mmol/g) and
DIPEA (210 µL) in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at
room tempertuare for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min.
The Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25
mL, 2 × 10 min) followed by washing with DMF (3 × 20 mL). The Fmoc-Lys (N3)-OH
(173 mg, 0.2 mmol) was coupled using HBTU (228 mg, 0.2 mmol) and DIPEA (210 µL)
in DMF for 1 h. The resin was washed with DMF (3 × 20 mL), and the Fmoc group was
removed using piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed
with DMF followed by reacting the the amino group with acetic anhdyride (Ac2O, 95 µL,
1 mmol) and DIPEA (174 µL, 1 mmol) in anhdyrous DMF (3 mL) for 30 min.
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The resin was washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried
in vaccum overnight before the final cleavage. A freshly prepared cleavage cocktail,
TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v, 10 mL), was added to the resin and
shaken at room temperature for 1.5 h. The resin was filtered and evaporated to reduce the
volume under dry nitrogen. The crude peptide was precipitated by adding cold diethyl
ether (200 mL, Et2O) and centrifuged at 4000 rpm for 5 min followed by decantation to
obtain the solid precipitate. The peptide was purified by reversed-phase HPLC using a
gradient system as described above, and the HPLC fractions were collected, evaporated
and lyophilized to obtain dry product (Scheme 3). ESI-TOF (m/z) [C14H27N9O3]: calcd,
369.2237; found, 370.2144 [M + H]+.

Synthesis of Amphiphilic Triazolyl Peptides by Click Chemistry of Peptides (Linear
or Cyclic) with Azide-Functionalized Positively Charged Linear Peptide
The click reaction was carried out in a 20 mL glass vial with small magnetic stir
bar by adding the alkyne linear peptide (7.46 mg, 8.68 µmol) or cyclic peptide (7.25 mg,
8.68 µmol)), CuSO4.5H2O (6.5 mg, 0.026 mmole), Cu powder (16.5 mg, 0.26 mmol),
sodium ascorbate (51.5 mg, 0.26 mmol), and azide-functionalized peptide, Ac-K(N3)RNH2 (10 mg, 0.026 mmol) in methanol:water (2:1v/v, 5 mL) followed by addition of
DIPEA (9 µL, 0.052 mmol). The mixture was stirred at room temperature for 24-48 h.
The completion of the reaction was confirmed by MALDI mass spectroscopy. The
reaction mixture was filtered, and the solvent was evaporated under reduced pressure to
afford the crude product. The crude product was further purified by HPLC using a
gradient system as described above, and the HPLC fractions were collected, evaporated
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and lyophilized to obtain solid compounds (Schemes 4 and 5). Cyclic-linear
[WG(triazole-KR-NH2)]4, MALDI-TOF (m/z) [C120H168N48O20]:

calcd, 2601.3605;

found 2621.1569 [M + H + H2O]+; Linear-linear (WG(triazole-KR-NH2))4 MALDI-TOF
(m/z) [C120H170N48O21]: calcd, 2619.3710; found 2621.1569 [M + 2 ]+, 2637.5587 [M +
H2O]+.

Amphilphilic Peptide Amide Derivatives

Synthesis of Linear Peptide (WE)3
The linear peptide was assembled on Rink amide resin (425 mg, 0.47 mmol, 1.1
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected
amino acids [Fmoc-Trp(Boc)-OH (315 mg, 0.2 mmol) and Fmoc-L-glutamic acid (225
mg, 0.2 mmol) (Scheme 6). The linear peptide sequence was assembled on the resin after
removing the Fmoc group at the N-terminal in the presence of 20% piperidine in DMF
(v/v) to obtain the sequence NH2-(E)W(Boc)(E)W(Boc)(E)W(Boc)-Rink amide resin.
The resin was washed with DMF/DCM and dried under vacuum for 24 h. Reagent R was
used to cleave the peptide from the resin. The crude peptide was precipitated by adding
filtrates to cold diethyl ether (200 mL, Et2O). The resulting solution was centrifuged at
4000 rpm for 5 min followed by decantation to obtain the solid precipitate. The peptide
was lyophilized and purified by reversed-phase HPLC using a gradient system as
described above to yield solid white colored linear peptide (WE)3 (Scheme 6). MALDITOF (m/z) [C48H54N10O12]: calcd, 962.3923 ; found, 986.6340 [M + Na]+, 1002.6207 [M
+ K]+.
84

Synthesis of Cyclic Peptide [WE]3
The linear protected peptide sequence was assembled using H-Trp(Boc)-2chlorotrityl resin (512 mg, 0.78 mmol, 1.5 mmol/g). The resin was swelled in DMF (3 ×
30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp (Boc)-OH
(632 mg, 0.4 mmol) and Fmoc-L-glutamic acid (638.25 mg, 0.4 mmol) and deprotection
cycle with piperidine in DMF (20% v/v). The final N-terminal Fmoc group was removed
to assemble the desired sequence NH2-(E)W(Boc)(E)W(Boc)(E)W(Boc)-2-chlorotrityl
resin (Scheme 7). The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL)
to remove any traces of piperdine. Side chain-protected peptides were cleaved from the
resins by agitating the peptidyl resin with cleavage cocktail, acetic acid/ 2,2,2trifluoroethanol (TFE)/dichloromethane (1:2:7, v/v/v, 50 mL), for 1 h at room
temperature followed by filtration and washing the resin with TFE:DCM (2:8 v/v, 20
mL). The collected filtrate was evaporated to reduce the volume. Hexane (2 × 25 mL)
and DCM (1 × 25 mL) were added to the residue to remove the acetic acid from the
residue. The solvents were evaporated to yield a fluffy white solid compound that was
dried overnight.
The cyclization of the protected crude solid peptide was carried out in the
presence of a mixture of the coupling reagents 1-hydroxy-7-azabenzotriazole (HOAt)
(162 mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol) in
anhydrous DMF:DCM (60/200 mL) for 24 h. The solvent was evaporated from a sample
solution (5 mL) under reduced pressure. Mass spectrometry confirmed the cyclization in
the residue.
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Thus, all the solvents were removed under reduced pressure that generated a high
viscous liquid. The final peptide cleavage to remove the side chain protection was carried
out

by

shaking

the

residue

with

cleavage

cocktail,

reagent

R,

TFA/thioanisole/anisole/EDT (90:5:2:3 v/v/v/v, 15 mL) for 2 h at room temperature. The
crude peptide was precipitated by the addition of cold diethyl ether (200 mL, Et 2O) and
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate.
The solid material was further washed with cold ether (2 × 100 mL). The crude peptide
was lyophilized and purified by reversed-phase HPLC (Hitachi L-2455) as described
above to yield cyclic peptide [WE]3 (Scheme 7). MALDI-TOF (m/z) [C48H51N9O12]:
calcd, 945.3657; found 968.1992 [M + Na]+.

Synthesis of Amino Functionalized Positively Charged Peptide (Ac-KR-NH2)
The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, FmocArg(Pbf)-OH and Fmoc-Lys-OH. The Rink amide resin was swelled with DCM (50 mL,
10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing
with DMF (3 × 30mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to
the peptidyl resin in the presence of HBTU (228 mg, 0.2 mmol/g) and DIPEA (210 µL)
in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at room
temperature for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min. The
Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25 mL, 2 × 10
min) followed by washing with DMF (3 × 20 mL).
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The Fmoc-Lys-OH (173 mg, 0.2 mmol) was coupled by using HBTU (228 mg,
0.2 mmol), DIPEA (210 µL) in DMF for 1 h. The resin was washed with DMF (3 × 20
mL), and Fmoc group was deprotected by using piperdine in DMF(20% v/v, 25 mL, 2 ×
10 min). The resin was washed with DMF, and the amino group was acetylated by
reaction with acetic anhdyride (AC2O, 95 µL, 1 mmol) and DIPEA (174 µL, 1 mmol) in
anhdyrous DMF (3 mL) for 30 min. The resin was again washed with DMF (3 × 30 mL),
DCM (3 × 30 mL), and then dried in vaccum overnight before the final cleavage. A
freshly prepared cleavage cocktail, TFA/ triisopropylsilane/ water (95:2.5:2.5 v/v/v, 10
mL), was added to the resin and shaken at room temperature for 1.5 h.
The resin was filtered and the filtrate was evaporated to reduce the volume under
dry nitrogen. The crude peptide was precipitated by adding cold diethyl ether (200 mL,
Et2O) and centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid
precipitate. The peptide was purified by reversed-phase HPLC using a gradient system,
and lyophilized to obtain the desired product (Scheme 8). ESI-TOF (m/z) [C14H29N7O3]:
calcd, 343.4354; found, 343.2140 [M]+.

Coupling of Amphiphilic Peptides (WE)3 and [WE]3 with Amino-Functionalized
Positively Charged Peptide (Ac-KR-NH2) via an Amide Bond.
The reaction was carried out in 20 mL round flask with small magnetic stir bar
by adding the amphiphilic peptide linear peptide (WE)3 (10 mg, 0.01 mmol) or cyclic
peptide [WE]3 (7.0 mg, 0.01 µmol), HOBT (1.8 mg, 0.01 mmole), benzotriazol-1yloxy) tripyrrolidino-phosphonium hexafluorophosphate (PyBOP, 14 mg, 0.1 mmol),
DIPEA (14 µL, 0.01 mmol), and amino-functionalized peptide, Ac-KR-NH2 (10.85
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mg, 0.01 mmol) in 2 mL of DMF. The mixture was stirred at room temperature for 1-2
h. The completion of the reaction was confirmed by MALDI mass spectroscopy. The
reaction mixture was filtered, and the solvent was evaporated under reduced pressure
to afford the crude product. The crude product was further purified by HPLC using a
gradient system, and the desired compound was lyophilized to dryness (Scheme 9).
Linear-linear (WE(AC-KR-NH2))3, MALDI-TOF (m/z) (C90H138N31O18): Calcd,
1938.0601; found 1954.1202 [M + H2O]+. Cyclic-linear [WG(AC-KR-NH2)]3
MALDI-TOF (m/z) [C90H132N30O18]: Calcd, 1921.0336; found 1925.0213 [M + 4H]+.

Amphiphilic Fatty Acyl Triazolyl Peptides
Synthesis of Stearic Propargyl Amide
Stearic acid (284.48 mg, 2.48 mmol) and hydroxybenzotriazole (HOBT, 544 mg,
0.4 mmol) were dissolved in 20 mL of anhydrous tetrahydrofuran (THF). Propargylamine
(160 µl, 2.50 mmol) was then added to the reaction at room temperature and the mixture
was cooled to 0 °C. A solution of dicyclohexylcarbodiimide (DCC) (511 mg, 2.48 mmol)
in 15 mL of anhydrous THF was added, and the mixture was stirred for 2 days at room
temperature. The reaction was monitored by TLC with hexane/ ethyl acetate 7:3 v/v as
the mobile phase. The reaction was filtered and the solvent was removed under reduced
pressure. Dichloromethane (250 mL) was added and the organic phase was washed three
times with 1 M of KHSO4 solution followed by three times with 1 M NaHCO3. The
organic layer was separated, and the solvent was removed under reduced pressure. The
resulting white solid was purified by recrystallization from ethanol (yield 75%), a white
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solid N-propargyl stearic amide (Scheme 10). MALDI-TOF (m/z) (C21H39NO): Calcd,
321.3032; found 322.2315 [M + H]+.

Synthesis of Myristic Propargyl Amide
Myristic acid (228.37 mg, 0.043 mmol) and hydroxybenzotriazole (HOBT, 654
mg, 4.3 mmol) were dissolved in 40 mL of anhydrous tetrahydrofuran (THF).
Propargylamine (275 µl, 2.50 mmol) was added to the reaction and the mixture was then
cooled to 0 °C. A solution of DCC (888 mg, 4.3 mmol) in 25 mL of anhydrous THF was
added, and the mixture was stirred for 2 days at room temperature. The reaction was
monitored by TLC with hexane/ethyl acetate 7:3 v/v as the eluent. The mixture was then
filtered, and the solvent was removed under reduced pressure. Dichloromethane (250
mL) was added, and the organic phase was washed three times with 1 M of KHSO4
solution followed by three times with 1 M NaHCO3. The organic layer was concentrated
under reduced pressure and the resulting white solid was purified by recrystallization
from ethanol (yield around 75%), a white solid N-propargyl myristic amide (Scheme 10).
MALDI-TOF (m/z) (C17H31NO): Calcd, 265.2406; found 266.2345 [M + H]+.

Synthesis of Protected Positively Charged Peptidyl Resin Functionalized with Azide
The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, FmocArg(Pbf)-OH and Fmoc-Lys(N3)-OH.The Rink amide resin was swelled with DCM (50
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mL, 10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing
with DMF (3 × 30 mL). Fmoc-Arg (Pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to
the peptidyl resin in the presence of HBTU (228 mg, 0.2 mmol/g) and DIPEA (210 µL)
in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at room
temperature for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min. The
Fmoc group was deprotected using piperidine in DMF (20% v/v, 25 mL, 2 × 10 min)
followed by washing with DMF (3 × 20 mL). Fmoc-Lys (N3)-OH (173 mg, 0.2 mmol)
was coupled using HBTU (228 mg, 0.2 mmol), DIPEA (210 µL) in DMF for 1 h. The
resin was washed with DMF (3 × 20 mL), and Fmoc group was deprotected by using
piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed with DMF
followed by acetylating the amino group in the presence of acetic anhdyride (Ac2O, 95
µL, 1 mmol) and DIPEA (174 µL, 1 mmol) in anhdyrous DMF (3 mL) for 30 min. The
resin was washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried under
vaccum overnight before the final cleavage. The peptide-attached resin remained
protected for coupling with fatty propargyl stearyl and myristoyl amide (Scheme 11).
MALDI-TOF (m/z) (C43H58N9O9S): Calcd, 876.4078; found 877. 0532 [M + H]+.

Click Reaction of Fatty Propargyl Amide with Positively Charged Arginine Azide
Click reaction was carried out in 20 mL round bottom flask with small magnetic
stir bar. Protected arginine azide (530 mg, 0.25 mmol) was swelled in DMF (50 mL × 3
for 10 min). Next, CuBr (18 mg, 0.13 mmol), sodium ascorbate (75 mg, 0.13 mmol),
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DIPEA (218 µl, 0.13 mmol), 2,6-lutidine (145µl, 0.13 mmol), stearic propargyl peptide
(120 mg, 0.125 mmol) or myristic propagyl peptide (99 mg, 0.125 mmol) were added.
The mixture was stirred at room temperature for 24-48 h. The completion of the reaction
was confirmed by MALDI mass spectroscopy. The reaction mixture was filtered, and the
solvent was evaporated under reduced pressure to afford the crude product. The crude
product was further purified by HPLC using a gradient system as described above, and
the HPLC fractions were collected, evaporated and lyophilized to obtain solid
compounds. Stearic Acyl Triazolyl peptide MALDI-TOF (m/z) [C35H66N10O4]: calcd,
690.5612; found 691.1710 [M + H]+ (Scheme 11); Myristic Acyl Triazolyl peptide
MALDI-TOF (m/z) [C31H58N10O4]: calcd, 634.8725; found 635.0931 [M + H]+ .

Results and Discussion
We reported the synthesis of amphiphilic linear and cyclic peptides containing
tryptophan (W) and arginine (R) connected through trizaole ring with proparglyglycine
(PG) in Chapter I. The compounds were characterized and evaluated for their potential
role as drug delivery tools. The peptides did not show any efficiency in improving the
cellular uptake possibly because of the limited number of three positively charged amino
acids in each peptide. Thus, there is a need to optimize amphiphilic peptides by
increasing the number of positive charged residues and hydrophobic residues to improve
the cell penetrating property of the peptides and to enhance the intracellular delivery of
bioactive compounds.
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To address the above issue, three classes of compounds were synthesized. In Class
I, linear-linear (WG(triazole-K(N3)R-NH2))4 and cyclic-linear [WG (triazole-K(N3)RNH2)]4 containing L-amino acids were synthesized using Fmoc-based peptide chemistry.
The linear peptide sequence (WpG)4 was assembled on the Fmoc-Rink amide resin using
solid-phase synthesis strategy. The last Fmoc group on the N-terminal was deprotected by
piperidine (20% v/v, DMF). Then the resin was dried, washed, and cleaved to afford the
linear peptide, which was purified by reversed-phase HPLC (Scheme 1). Synthesis of
cyclic peptide was accomplished by assembling of the linear protected peptide (WpG) on
the H-Trp (Boc)-2-chlorotrityl chloride resin. The side chain protected group was
removed, and the peptide was again purified using HPLC (Scheme 2). The synthesis of
azide-functionalized positively charged peptide building block (Ac-K(N3)R-NH2) was
performed on Rink amide resin. The Fmoc group was deprotected, and amino group was
acetylated using acetic anhydride in DMF. The peptide was cleaved from the resin and
purified by HPLC to afford Ac-K(N3)R-NH2 (Scheme 3).
Click chemistry reactions were performed by coupling linear-linear and cycliclinear peptides containing alkyne, (W(pG))4 and [W(pG)]4, and the azide-functionalized
linear peptide Ac-K(N3)R-NH2 in solution phase using CuSO4.5H2O, Cu powder, sodium
ascorbate, and N,N-diisopropylethylamine (DIPEA) in methanol:water for 24-48 h. The
formation of the conjugated products was confirmed by MALDI-TOF mass spectroscopy
(Schemes 4 and 5).
In Class II, new amphiphilic peptides amide derivatives were synthesized. The
purpose was to compare the triazole peptides derivatives with the corresponding amide
peptides for their role as molecular transporter. Linear and cyclic tryptophan and glutamic
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acid containing peptides were connected through amide bonds with the lysine residue in
Ac-KR-NH2. Linear-linear (WE(AC-KR-NH2))3 and cyclic-linear [WE(AC-KR-NH2)]3
peptides were again synthesized using Fmoc-based peptide chemistry. The linear peptide
sequence (WE)4 was assembled on the Fmoc-Rink amid resin using solid-phase synthesis
strategy. The last Fmoc group on the N-terminal was deportected by piperidine (20% v/v,
DMF). Then the resin was dried, washed, and cleaved to afford the linear peptide which
was purified by reversed-phase HPLC (Scheme 6). Synthesis of cyclic peptide was
accomplished by assembly of the linear protected peptide (WE)4 on the H-Trp(Boc)-2chlorotrityl chloride resin. The side chain protected group was removed, and the peptide
was purified using HPLC (Scheme 7).
The synthesis of functionalized positively charged peptide building block (AcKR-NH2) was performed on Rink amide resin. The Fmoc group was deprotected, and
amino group was acetylated using acetic anhydride in DMF. The peptide was cleaved
from the resin and purified by HPLC to afford Ac-KR-NH2 (Scheme 8). The coupling
reaction was performed by adding (WE)3 and [WE]3, and an amino-functionalized
peptide, Ac-KR-NH2, in DMF in the presence of the coupling reagents HOBT, PyBOP,
DIPEA.

After HPLC purification, the formation of the product was confirmed by

MALDI-TOF mass spectroscopy (Scheme 9).
In Class III, two Amphiphilic Fatty Acyl Triazolyl Peptides (AFTP) derivatives
were synthesized using peptides containing arginine and lysine azide (AC-K(N3)R-NH2).
Myristic acid and stearic acid were coupled to propagylamine in the presence of HOBT in
THF. Positively charged peptidyl resin functionalized with an azide group was
synthesized by assembling the peptide on Rink amide resin using Fmoc-Arg(Pbf)-OH
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and Fmoc-Lys(N3)-OH. After Fmoc removal and capping of the peptides by acetic
anhdyride, click chemistry was used to react the myristic propargyl and stearic propargyl
amides in the presence of CuBr, sodium ascorbate to afford the stearic triazolyl peptide
and myristic triazolyl peptides (Schemes 10 and 11).

Conclusion
In conclusion, three classes of amphiphilic peptides were synthesized to be
evaluated as molecular transporters and antibacterial agents. Fmoc-based peptide
synthesis, click chemistry, and amide bond formation were used in the synthesis of
compounds. In the future, the physicochemical properties, cytotoxicity, nanostructure
formation, molecular transporter efficiency, and antibacterial activity of these compounds
will be evaluated and compared with linear-linear (WG(triazole-KR-NH2))3 and cycliclinear [WG(triazole-KR-NH2)]3 in Manuscript I.
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Figure legends.

Figure 1. Chemical structures of three classes of amphiphilic peptides.
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Figure 1.
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Scheme Legends:

Scheme 1. Synthesis of linear (W(pG))4.
Scheme 2. Synthesis of cyclic [W(pG)]4.
Scheme 3. Synthesis of positively charged peptides containing an azide.
Scheme 4. Click Chemistry of to react the propargyl groups on a linear peptide with
azides on a positively charged peptide.
Scheme 5. Click Chemistry of to react the propargyl groups on a cyclic peptide with
azides on a positively charged peptide.
Scheme 6. Designing of linear (WE)3 amide derivatives of amphiphilic peptides.
Scheme 7. Designing of cyclic [WE]3 amide derivatives of amphiphilic peptides.
Scheme 8. Synthesis of positively charged peptides with arginine and lysine residues.
Scheme 9. Coupling of cyclic amphiphilic peptides by creation of an amide bond.
Scheme 10. Synthesis of stearyl propargyl amide and myristyl propargyl amide
building blocks.
Scheme 11. Synthesis of positively charged protected peptidyl resin functionalized
with azide and click chemistry to react fatty acyl propargyl amides with azides on
arginine containing units.
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Scheme 2.
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Scheme 3.
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Scheme 4.
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Scheme 5.
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Scheme 7.
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Scheme 8.
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Scheme 9.
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Scheme 11.
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